Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 3-Deazaneplanocin A. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 0.97 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.97 |
| ▸ | AHCYL1 | O43865 | 2/20 | 0.63 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Deazaneplanocin A SCHEMBL20595432 | 1.00 | AHCY (0.97) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL4304150 | 1.00 | AHCY (0.97) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL12280318 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL874126 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL12321313 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL23683021 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL863851 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL1521229 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL18256281 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL29358420 | 0.99 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263669-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | UNIV TSINGHUA (CN) | 2025-08-21 | — | — | US | claimed |
| EP-4394030-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | Tsinghua University (CN) | 2024-07-03 | — | — | EP | claimed |
| CN-118147053-A | Culture system, kit and method for inducing mesenchymal stem cells | 成都赛济元生物医药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118048296-A | Culture system, kit and method for reprogramming cells | 成都赛济元生物医药有限公司 | 2024-05-17 | — | — | CN | claimed |
| EP-4271399-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2023-11-08 | — | — | EP | claimed |
| CN-115725495-A | Induced totipotent stem cell and preparation method thereof | 清华大学 | 2023-03-03 | — | — | CN | claimed |
| WO-2023025302-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | 清华大学 | 2023-03-02 | — | — | WO | claimed |
| US-20220233646-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-28 | — | — | US | claimed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220144902-A1 | METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE | NIPPON SHINYAKU CO., LTD. (JP) | 2022-05-12 | — | — | US | claimed |
| EP-3990624-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2022-05-04 | — | — | EP | claimed |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260015582-A1 | METHODS OF T CELL DIFFERENTIATION AND COMPOSITIONS THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250354117-A1 | METHODS OF GENERATING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | CHILDRENS MEDICAL CT CORP (US) | 2025-11-20 | — | — | US | disclosed |
| US-20220144902-A1 | METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE | NIPPON SHINYAKU CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3990624-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | disclosed |
| EP-3954382-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-3949983-A1 | WATER SOLUBLE ADJUVANT | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015582-A1 | METHODS OF T CELL DIFFERENTIATION AND COMPOSITIONS THEREOF | CD4, CD47, CD63 | AHCY 962/4885EZH2 776/4885AHCYL1 787/4885 |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | IAPP, CBX6, HLA-C | AHCY 2937/4885EZH2 226/4885AHCYL1 556/4885 |
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, PNLIP, PPARD | AHCY 3680/4885EZH2 1796/4885AHCYL1 3438/4885 |
| US-20220233646-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, AMY2A, RNASE1 | AHCY 1973/4885EZH2 2680/4885AHCYL1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.